Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Updated Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

Updated Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

普拉替尼治療中國RET融合陽性的局部晚期或轉移性非小細胞肺癌患者的真實世界療效及安全性研究

GEMSTONE-201: 舒格利單抗治療復發難治性結外 NK/ T 細胞淋巴瘤(R/R ENKTL） 的多中心、單 臂 、II 期臨床研究

GEMSTONE-201: pre-planned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL)

Sugemalimab vs placebo after concurrent or sequential chemoradiotherapy in patients with unresectabl (GEMSTONE-301): final progression-free survival analysis of a phase 3 study